Back to results
US 11,124,560 B2Granted
Stable pooled breastmilk antibodies for oral delivery
AssigneeLactiga, Inc.
InventorsViraj Mane, Rikin Mehta
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeLactiga, Inc.
InventorsViraj Mane, Rikin Mehta
Estimating the term…
Methods are provided for extracting and purifying maternal antibodies from breastmilk, followed by further processing to facilitate oral ingestion. The methods may be used on breastmilk from any mammal, including humans, for consumption by mammals including humans. Antibodies are well-known immune mediators that are naturally found in abundant supply in breastmilk, and they are passed directly to the offspring via breastfeeding. The methods described herein extract antibodies from breastmilk in a manner that preserves the structure and antigen-specificity while enabling the formulation into products that are optimized for delivery to mammals, including humans. The method comprises (1) breastmilk collection, (2) extraction of antibodies, (3) characterization of antibody structure, degradation, and contamination, and (4) formulation into a dietary supplement (food product) for delivery to mammals, especially humans.
A composition of human antibodies substantially free of non-antibody components, the composition comprising purified human IgA with human-specific immunogenicity derived from a sample of non-pasteurized breastmilk, wherein the composition comprises intact antibodies representing more than 81% of total antibodies, the total antibodies comprising the intact antibodies and degraded antibodies, the composition having stability at 25° C. for at least 14 days.
An oral dosage form made using the composition of 1.
A method for preparing an antibody composition, comprising the steps of:
A composition of human antibodies substantially free of non-antibody components, the composition comprising purified human IgA with human-specific immunogenicity derived from a sample of non-pasteurized breastmilk using an ammonium sulfate precipitation with an ammonium sulfate concentration of approximately 45% to 65%, and an immunoglobulin purification column comprising capture antibodies for IgA, IgG, and IgM, wherein the composition comprises intact antibodies representing more than 81% of total antibodies, the total antibodies comprising the intact antibodies and degraded antibodies, the composition having stability at 25° C. for at least 14 days.
Dependencies are inferred from the claim text.